Shimadzu has released a new and unique fully automated sample preparation module (RUO) connected online for LC-MS to the four major clinical research markets in Europe, i.e. Germany, France, Italy and Spain. The CLAM-2000*(Clinical Laboratory Automated sample preparation Module) automates the pretreatment of blood or other biological samples before LCMS analysis. It is designed for customers handling blood samples in pharmaceutical departments, medical departments or biological analysis laboratories dealing with issues of variability in analytical results or infection risk.
In recent years, there has been considerable progress in the use of mass spectrometers (MS) in the clinical research field due to their highly sensitive detection and high specificity as well as the possibility of multiplexing analysis without the risk of cross reactions inherent to immuno-assays. Mass spectrometry enables direct detection of disease related biological compounds in blood, urine or other biological samples, measurement of trace concentration levels of drugs as well as other applications. However, the bottleneck is still sample preparation which is often tedious, involves risk of errors and increases the risk of contamination of people dealing with sample preparation.
Completely automatic from pretreatment to analysis
By simply placing blood collection tubes in the system, the CLAM-2000 performs all processes through to LC-MS analysis automatically. Unlike dispensing systems based on batch processing 96-well plates, the CLAM-2000 is completely automatic from pretreatment to analysis and processes individual sample successively in parallel. Consequently, it results in uniform pretreatment times between samples without slowing processing speed, while improving data reproducibility and accuracy.
Pretreatment processes available include dispensing samples, dispensing reagents, stirring, suction filtration, incubation and automatic transfer of sample vials to an SIL-30AC autosampler after pretreatment.
World's first
Consequently, the new CLAM-2000 is the first system in the world able to perform all steps fully automated from pretreatment of the sample to LC-MS analysis, requiring only the simple task of placing the blood or biological fluid collection tubes, reagents, internal standards and specialized pretreatment vials in the system. It also features excellent management functions providing a dramatically improved workflow with better safety for clinical research and higher reproducibility. It is compatible with the LC-MS TQ systems LCMS-8040, LCMS-8050 and LCMS-8060, giving a large choice to adapt to sensitivity needs.
*For Research Use Only. Not for use in diagnostic procedures.
Not available in the USA, Canada and China.
For more information please visit www.shimadzu.eu
Full Tolerance Coverage Method for Assessing Uniformity of Dosage Units with Large Sample Sizes
March 10th 2025The ‘full tolerance coverage method’ is introduced as a coverage estimation approach for assessing the uniformity of dosage units from large sample sizes, ensuring that no dosage unit exceeds the specification range.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Inspiration Over Desperation: Accurant Biotech CEO Talks Leadership, Innovation, and Motivation
March 4th 2025Xiao-Yan Cai, PhD, shares insights into her leadership style, the importance of motivation in the workplace, and how she balances repetition with innovation, discussing how hobbies and resilience uniquely shape her professional approach, emphasizing the value of perseverance and preparation in both science and life.
Specification Equivalence—A Practical Approach
December 30th 2024In this first of a four-part series, the authors provide an introduction to a practical approach for establishing specification equivalence. The regulatory basis and compliance examples from FDA observations and warning letters are included to support the need for an effective process.